NCT06212752 2025-11-12
MK-3475A-D77
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05722015 2025-09-11
MK-3475A-D77
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04174599 2025-04-20
Study to Compare the Efficacy and Safety of F-627 and GRAN®
EVIVE Biotechnology
Phase 3 Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT03504410 2023-02-08
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals
Phase 3 Terminated
NCT03343145 2020-12-28
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
Dong-A ST Co., Ltd.
Phase 3 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT01519700 2015-05-06
PIONEER
Sandoz
Phase 3 Completed
NCT01767714 2014-12-09
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Sanofi
Phase 3 Completed
NCT01079676 2012-10-16
A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer
Eurofarma Laboratorios S.A.
Phase 3 Completed
NCT00776165 2010-02-03
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
Shantha Biotechnics Limited
Phase 3 Completed